• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
lutein
Bamboo Leaf Extract
TZ-SN01 Prefilled Single-nozzle Nasal Spray Device
TZ-YN01 Prefilled Double-nozzle Nasal Spray Device
TZ-50/100AE Airless Drug Delivery Systems (Airless Container)
TPF 14 Topical Liquid Medicinal Bottle Set

Lupin gets tentative approval from USFDA for Efinaconazole Topical Solution

expresspharmaDecember 28, 2020

Tag: lupin , FDA , Efinaconazole Topical Solution , Trichophyton mentagrophytes , Trichophyton rubrum

Lupin has received tentative approval for its Efinaconazole Topical Solution, 10%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Jublia Topical Solution, 10%, of Bausch Health Americas.

Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Efinaconazole Topical Solution, 10%,(RLD: Jublia) had estimated annual sales of $222.9 million in the US (IQVIA MAT September 2020).

Previous:M&As in bio/pharma industry high despite COVID-19: GlobalData

Next:Zydus seeks approval for Phase III clinical trials of ZyCoV-D, submits Phase I/II clinical trial data

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Lupin gets tentative approval from USFDA for Efinaconazole Topical Solution | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals
Lupeol-8%-Lupinus Albus Extracts

Lupeol-8%-Lupinus Albus Extracts
Ifosfamide (FDA)

Ifosfamide (FDA)
4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）

4,4'-(Hexafluoroisopropylidene)diphthalicanhydride (6FDA）
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
9,9-Bis(4-aminophenyl) Fluorene (FDA)

9,9-Bis(4-aminophenyl) Fluorene (FDA)
Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)
Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service